Overview Fundamentals API Earnings EOD API Sample Code Pricing

Spyre Therapeutics Inc. (SYRE NASDAQ) stock market data APIs

$26.89 -1.1(-3.9%) as of December 4, 2024
Price chart is built with Anychart

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics Inc. Financial Data Overview

27.99
26.89
-
28.18
26.87
14.22-47.97
1 643 M
58 706 K
0
-1.36
2.91
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'SYRE',
Type: 'Common Stock',
Name: 'Spyre Therapeutics Inc.',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0067L94B2',
ISIN: NULL,
CUSIP: NULL,
CIK: '1636282',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2016-04-07',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Spyre Therapeutics Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -194 508 992
  • Earnings Per Share -37.9
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Spyre Therapeutics Inc. Earnings via APIs

  • Latest Release 2024-11-07
  • EPS/Forecast -0.82

Get Spyre Therapeutics Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com